Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate. Doctors and scientists have long struggled to ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma. Jaime Merchan, MD, professor, co-leader ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Ibrance is under clinical development by Pfizer and currently in Phase III for Head And Neck Squamous Cell Carcinoma (HNSC).

1 Department of Oncology, Affliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China 2 Department of GCP, Affliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China ...

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment.

Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.

Renal cell carcinoma (RCC) is the most common tumor of the kidney, constituting 80% to 85% of primary renal neoplasms. Clear cell RCC (ccRCC) is the most common subtype, accounting for 80% of all RCCs ...

FBXO8 was overexpressed using a plasmid, and we assessed Kidney renal clear cell carcinoma (KIRC) cell proliferation, migration, and apoptosis through CCK8, wound healing tests, and western blot ...

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate.